Antimetastatic effect of ganoderic acid T in vitro through inhibition of cancer cell invasion

Process Biochemistry

Volumn 45, Issue 8, 2010, Pages 1261-1267

  Xu, Ke ^a   Liang, Xin ^a   Gao, Feng ^a   Zhong, Jianjiang ^a   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Ganoderic acid T; Invasion; Metastasis; MMPs; NF B

Indexed keywords

ACTIVE COMPONENTS; ADHESION ASSAYS; CANCER CELLS; CELL AGGREGATION; EXTRACELLULAR MATRICES; GANODERIC ACID; GANODERMA LUCIDUM; IN-VITRO; LUNG CARCINOMA; PCR ASSAY; PROTEIN LEVEL; THERAPEUTIC POTENTIALS; TRITERPENES; TRITERPENOIDS; TUMOR METASTASIS; WESTERN BLOTS; WOUND HEALING;

ACIDS; ENZYME INHIBITION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEAD COMPOUNDS; TUMORS;

PATHOLOGY;

FUNGI; GANODERMA LUCIDUM;

EID: 77954088353     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2010.04.013     Document Type: Article

References (34)

1. Valsasa H., Masahiro H., Gamini S.J. Avicins: triterpenoid saponins from Acacia victoriae (bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci USA 2001, 98:5821-5826.
2. Stadheim T.A., Suh N., Ganju N., Sporn M.B., Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem 2002, 277:16448-16455.
3. Thangaiyan R., Anupam B. Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat 2009, 115:223-239.
4. Gao Y.H., Zhou S.F. Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food Rev Int 2003, 19:275-325.
5. Harhaji Trajković L.M., Mijatović S.A., Maksimović-Ivanić D.D., Stojanović I.D., Momcilović M.B., Tufegdzić S.J., et al. Anticancer properties of Ganoderma lucidum methanol extracts in vitro and in vivo. Nutr Cancer 2009, 61(5):696-707.
6. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem 2004, 4:873-879.
7. Liu X., Yuan J.P., Chung C.K., Chen X.J. Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett 2002, 182:155-161.
8. Lu Q.Y., Sartippour M.R., Brooks M.N., Zhang Q., Hardy M., Go V.L., et al. Ganoderma lucidum spore extract inhibits endothelial and breast cancer cells in vitro. Oncol Rep 2004, 12:659-662.
9. Tang W., Gu T.Y., Zhong J.J. Separation of targeted ganoderic acids from Ganoderma lucidum by reversed phase liquid chromatography with ultraviolet and mass spectrometry detections. Biochem Eng J 2006, 32:205-210.
10. Sliva D., Sedlak M., Slivova V., Valachovicova T., Lloyd F.P., Ho N.W. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 2003, 9:491-497.
11. Kato R., Ishikawa T., Kamiya S., Oguma F., Ueki M., Goto S., et al. A new type of antimetastatic peptide derived from fibronectin. Clin Cancer Res 2002, 8:2455-2462.
12. Sancéau J., Truchet S., Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003, 278:36537-36546.
13. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metast Rev 1990, 9:289-303.
14. Kimura Y., Taniguchi M., Baba K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res 2002, 22(6A):3309-3318.
15. Chen N.H., Liu J.W., Zhong J.J. Ganoderic acid Me inhibits tumor invasion through down-regulating matrix metalloproteinases 2/9 gene expression. J Pharmacol Sci 2008, 108(2):212-216.
16. Smilack J.D. The tetracyclines. Mayo Clin Proc 1999, 74:727-729.
17. Fife R.S., Rougraff B.T., Proctor C., Sledge G.W.J. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997, 130:530-534.
18. Fife R.S., Sledge G.W.J., Roth B.J., Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett 1998, 127:37-41.
19. Fife R.S., Sledge G.W.J., Sissons S., Zerler B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000, 153:75-78.
20. Fife R.S., Sledge G.W.J. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995, 125:407-411.
21. Xu W., Liu J.W., Li C., Wu H.Z., Liu Y.W. Kaempferol-7-O-β-d-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Lett 2008, 264:229-240.
22. Liu J.W., Kayasuga A., Nagao N., Masatsuji-Kato E., Tuzuki T., Miwa N. Repressions of actin assembly and RhoA localization are involved in inhibition of tumor cell motility by lipophilic ascorbyl phosphate. Int J Oncol 2003, 23:1561-1567.
23. Zhenyu Z., Sanchez-Sweatman O., Xiaojun H., Robert W., Rama K., Qun Z., et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001, 61:1516-1707.
24. Glinsky G.V., Glinsky V.V. Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 1996, 101:43-51.
25. Subha P., Anuradha B., Gopal C.K. Matrix metalloproteinase-2: mechanism and regulation of NF-κB-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate J 2004, 21:429-441.
26. Sugiyama T., Sadzuka Y. Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clin Cancer Res 1999, 5:413-416.
27. Glinsky V.V., Huflejt M.E., Glinsky G.V., Deutscher S.L., Quinn T.P. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on β-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 2000, 60:2584-2588.
28. Matsuyoshi N., Hamaguchi M., Taniguchi S., Nagafuchi A., Tsukita S., Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992, 118:703-714.
29. Maria V.C., Immacolata L.C., Katia B., Ornella M., Liliana L., Antonio B., et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther 2009, 8:2708-2709.
30. Mareel M., Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003, 83:337-376.
31. Elkin M., Reich R., Nagler A., Aingorn E., Pines M., de-Groot N., et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999, 5:1982-1988.
32. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer I 2001, 93:178-193.
33. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001, 276:44926-44935.
34. Han Y.P., Tuan T.L., Wu H., Hughes M., Garner W.L. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa) B mediated induction of MT1-MMP. J Cell Sci 2000, 114:131-139.